CONMED earnings beat by $0.04, revenue fell short of estimates
CONMED (CNMD) reported Q3 EPS of $1.04, beating estimates by $0.04, but revenue of $335.6M missed expectations of $336.28M. The company guided FY 2026 EPS to $4.54-$4.61 and revenue to $1.36B-$1.37B, slightly below consensus. The stock is down 1.17% over the last 3 months and 2.03% over the last 12 months.
How this was made
The 30-second read
Why it matters
The modest beat and flat guidance suggest limited upside, with potential for short‑term downside as investors reassess growth expectations.
Market read
Earnings release provides fresh data for traders; the guidance may influence short‑term price action.
What to watch
No major contract wins or product launches were disclosed, which could have provided upside.
Background
CONMED (CNMD) posted Q3 results with a small earnings beat and provided FY 2026 guidance that is roughly in line with consensus for EPS but slightly below for revenue.
Ticker impact
CONMED reported Q3 EPS of $1.04, beating estimates by $0.04 and gave FY 2026 EPS guidance of $4.54‑$4.61.
potential modest downside as revenue guidance is at the low end of expectations
The beat is small and guidance is flat to slightly below consensus, limiting upside and possibly prompting profit‑taking.
Market effects
Medical device sector may see limited impact; earnings beat is modest.
U.S. small‑cap market may see slight pressure on similar peers.
Low; the news is company‑specific.
Counterpoint
Despite the beat, the flat guidance could signal underlying demand weakness.
Key entities
- CompanyCONMED
Medical device manufacturer reporting Q3 earnings.
